PIA
ONCE

Piedmont Investment Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Piedmont Investment Advisors’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-546
Closed -$45K – 2782
2018
Q2 		$45K Buy
+546
New +$42.1K ﹤0.01% 1327

Other funds holding ONCE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Piedmont Investment Advisors's ONCE Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2018, closing a stake of 546 shares — an estimated $45K sold.

Piedmont Investment Advisors first reported a position in ONCE in Q2 2018 and held it in 1 quarter. The position peaked at $45K in Q2 2018. 176 funds tracked by Wall St. Rank hold ONCE as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 546 Spark Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $45K.
  • Piedmont Investment Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $45K in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.